LMOD1 expression and survival in uterine leiomyosarcoma: discordant results in tissue microarrays and whole sections
Authors:
- Ben DavidsonBDBen Davidson
- Arild HolthAHArild Holth
- Guro Horni GløersenGGGuro Horni Gløersen
Open Access
- 27 October 2026
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 215, 7-15
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Uterine leiomyosarcomaInternational Journal of Gynecological Cancer, 2025
- Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine LeiomyosarcomaInternational Journal of Gynecological Pathology, 2024
- Cyclin-dependent kinase 8 is an independent prognosticator in uterine leiomyosarcomaPathology - Research and Practice, 2022
- Insulin‐like growth factor II messenger RNA‐binding protein‐3 is an independent prognostic factor in uterine leiomyosarcomaHistopathology, 2018
- Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcomaVirchows Archiv, 2017
- Loss of LMOD1 impairs smooth muscle cytocontractility and causes megacystis microcolon intestinal hypoperistalsis syndrome in humans and miceProceedings of the National Academy of Sciences, 2017
- Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcomaScientific Reports, 2016
- Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine LeiomyosarcomaAmerican Journal of Clinical Pathology, 2016
- Leiomodin 1, a New Serum Response Factor-dependent Target Gene Expressed Preferentially in Differentiated Smooth Muscle CellsJournal of Biological Chemistry, 2012
- Diagnostic Immunohistochemistry in Uterine SarcomasInternational Journal of Gynecological Pathology, 2011